Featured image via FreePik/jcomp
President Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III marks one of the most consequential federal cannabis actions in decades. While the announcement has sparked headlines and strong reactions across the industry, rescheduling is best understood as a shift in posture, not a finish line.
For an industry long caught between state legality and federal prohibition, this moment offers both opportunity and unanswered questions.
What Rescheduling Actually Means
Under the Controlled Substances Act, Schedule I substances are defined as having no accepted medical use. Cannabis has remained in that category despite decades of state-level medical programs and widespread consumer adoption.
Moving cannabis to Schedule III formally acknowledges medical use at the federal level. But it does not remove the legal gray zones that leave many operators and consumers exposed to federal risk.
Interstate commerce remains prohibited, and state licensing systems continue to govern dispensaries, growers, and manufacturers.
In short, rescheduling changes cannabis’s classification, not its legal status.
Why This Matters for Businesses
One of the most immediate and tangible impacts of rescheduling is tax-related. As long as cannabis remains classified as Schedule I or II, businesses are subject to IRS rule 280E, which prevents them from deducting ordinary operating expenses. For many operators (especially small and independent ones), this has meant razor-thin margins or outright failure.
Tim Barash, chairman and CEO of Dutchie and co-chair of the Coalition for Cannabis Scheduling Reform, emphasized the significance of this shift in a statement to The Emerald:
“One of the most immediate impacts of rescheduling is the end of the 280E tax penalty, removing a long-standing barrier to growth. This change will also bring in large institutions and services across the business and banking world, allowing this major U.S. industry to have the same support as the rest of our economy.”
Rescheduling could also improve access to financial services, insurance, and institutional capital.There are areas where cannabis businesses have historically faced steep barriers due to federal classification.
Regulatory Clarity–or More Confusion?
For many industry leaders, the real test of rescheduling lies in what comes next.
Kim Sanchez Rael, CEO and co-founder of Azuca, framed the move as a signal rather than a solution:
“Federal rescheduling would be a meaningful signal that U.S. cannabis policy is beginning to catch up with reality. But as with all policy moments in this industry, the signal alone is not the outcome. The details matter, and alignment matters even more.”
She noted that if rescheduling is paired with clear and consistent guidance—particularly around hemp and cannabinoids—it could reduce years of regulatory ambiguity that have stalled innovation and forced compliant operators to navigate constant uncertainty.
Without that clarity, the industry risks layering fragmented advocacy on top of fragmented policy.
Research, Patients, and Medical Recognition
Rescheduling also opens doors on the medical and research side of cannabis. Schedule III substances are recognized as having medical value, which can ease restrictions on scientific study and product development.
Brooks Jorgensen, president of Canopy USA, highlighted this potential.“Rescheduling provides greater regulatory clarity for operators and helps unlock a more sustainable business environment, supporting access to research, improving patient care, and expanding safe, regulated options for consumers.”
For patients, this recognition matters—not just symbolically, but practically, as it supports evidence-based approaches to medical cannabis and cannabinoid therapies.
What Rescheduling Does Not Do
Despite the scale of the announcement, several realities remain unchanged:
- Cannabis is still federally illegal
- State markets still operate in conflict with federal law
- Rescheduling does not decriminalize cannabis or erase past convictions
- Home cultivation rules remain state-specific
- Drug testing policies are unaffected
As Scott Davido, CEO of Ayr Wellness, noted, this is a step—not an endpoint. “This marks a major step towards unlocking further research into the medical efficacy of cannabis and allowing fair tax treatment for the cannabis industry… Alongside our peers, we continue to advocate for further cannabis reform federally and at the state level.”
Progress, With Conditions
Rescheduling represents movement after years of stalled federal action. It acknowledges medical reality, eases certain business pressures, and creates a pathway for more functional policy. But it also leaves prohibition largely intact. And it places enormous weight on how regulators, lawmakers, and industry stakeholders choose to proceed.
As Sanchez Rael cautioned, true reform depends on alignment.
“What we cannot afford right now is fragmented advocacy layered on top of fragmented policy… True reform doesn’t come from noise. It comes from alignment. And it will never be true reform until there is also justice for those wronged by prohibition and disparate enforcement.”
The Upshot
Cannabis rescheduling is not a reset button, and it isn’t the end of prohibition. It is a recalibration. One that acknowledges medical use, eases specific pressures on legal businesses, and creates space for more functional federal policy if lawmakers and regulators choose to act with intention.
It could create new opportunities, but it also leaves many systemic challenges in place.
What happens next matters more than the announcement itself. Clear guidance, coordinated advocacy, and a commitment to fairness will determine whether this shift leads to stability or simply reshuffles existing challenges under a new classification.
For the cannabis industry, this moment rewards preparedness and responsibility. For consumers and patients, it signals a gradual move away from outdated frameworks toward regulation that reflects how cannabis is actually used today. And for communities still carrying the harm of prohibition, rescheduling alone is not enough. Real progress must include accountability and justice.
This is not the finish line. It is a hinge point. What comes after will define whether federal cannabis policy finally begins to function in the real world.
Leave a Reply